Formycon AG (FSB: FYB, Prime Standard) announced today that it will publish its financial results for the 2025 fiscal year on April 22, 2026. The management board will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call scheduled for the same day at 3:00 PM CEST. The call will be broadcast live in English and will include a presentation followed by a question-and-answer session for analysts. Registration for the conference call is available at https://webcast.meetyoo.de/reg/lNibT8TVWubG, and the presentation and audio broadcast can be accessed via https://www.webcast-eqs.com/formycon-2025-fy. A recording will be available afterward on the Formycon website at https://www.formycon.com/en/investor-relations/publications/.
In addition to the annual results, Formycon representatives will attend several investor conferences in the second quarter of 2026. These include the Equity Forum Spring Conference in Frankfurt on May 11–12, where CFO Enno Spillner will be present; the publication of first quarter 2026 results on May 28, with a conference call led by CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl; the Jefferies Global Healthcare Conference in New York City from June 2–4, with CFO Spillner; the mwb research Roundtable webcast on June 8; the Annual General Meeting in Munich on June 10; and the UBS Life Sciences Conference in London on June 18, with CFO Spillner. A full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
Formycon is a leading independent developer of high-quality biosimilars, focusing on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers almost the entire value chain from technical development through clinical trials to regulatory approval. For commercialization, Formycon relies on strong, long-term partnerships worldwide. The company already has two biosimilars on the market: FYB201/ranibizumab and FYB202/ustekinumab. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates, including FYB208/dupilumab, are currently in development. Through its biosimilars, Formycon aims to expand patient access to effective and affordable biopharmaceutical medicines.
The biosimilar market is poised for significant growth as patents for many biopharmaceutical drugs expire. By 2032, an estimated 45 blockbuster drugs with combined annual sales of over $200 billion will lose patent protection. Biosimilars, which are approved under strict regulatory pathways in markets such as the EU, USA, Canada, Japan, and Australia, create competition and reduce healthcare costs. Global biosimilar sales currently amount to approximately $21 billion, and analysts project they could exceed $74 billion by 2030. Formycon is well positioned to capitalize on this trend with its robust pipeline and commercial partnerships.
